Patients with urinary NGAL<90.75 ng/ml can be treated with aggressive volume expansion therapy, but patients with cirrhosis and AKI with urinary NGAL>90.75 ng/ml before treatment may not respond to volume expansion therapy. This evidence concerns the gene LCN2 and acute kidney injury.